NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Sponsor: Nanobiotix
A PHASE1 clinical study on Immunotherapy and Metastasis From Malignant Melanoma of Skin (Disorder), this trial is ongoing. The trial is conducted by Nanobiotix and has accumulated 17 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
17 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 12 earlier versions
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Feb 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
Feb 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Feb 2020 — Nov 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting · Phase: PHASE1_PHASE2 → PHASE1
-
Aug 2018 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nanobiotix
For direct contact, visit the study record on ClinicalTrials.gov .